# Dermal Exposure to Heavy Metals in Urban Green Space Soils: A Review of Bioavailability, Toxic Mechanisms, and Precision Risk Assessment

**Authors:** Yiping Cheng, Daolei Cui, Zhaolai Guo, Wei Hong, Yue Li, Chin Wei Lai, Ping Xiang

PMC · DOI: 10.3390/toxics14030236 · Toxics · 2026-03-10

## TL;DR

This paper reviews how heavy metals in urban green space soils can be absorbed through the skin and proposes a more accurate method for assessing health risks.

## Contribution

The paper introduces a precision risk assessment framework that integrates bioavailability and skin-specific factors for dermal exposure to heavy metals.

## Key findings

- Traditional risk assessments overestimate threats by ignoring bioavailability and skin microenvironment factors.
- Soil properties and metal speciation significantly influence cutaneous uptake of heavy metals.
- Case studies show uneven heavy metal distribution in high-traffic urban areas.

## Abstract

Urban green spaces (UGSs) provide essential ecological services but also accumulate heavy metals (HMs) in their soils, posing a paradoxical health risk through dermal exposure. Traditional risk assessments, based solely on total HM concentrations, often overestimate threats by ignoring bioavailability (the fraction actually absorbed by organisms) and dynamic skin microenvironment factors. This review synthesizes recent advances to propose a precision assessment framework that integrates bioavailability. The framework advocates for the incorporation of bioaccessibility (the fraction of pollutants dissolved in body fluids)-driven exposure metrics (e.g., physiologically based extraction tests), mechanistic dermal permeation models (e.g., Franz diffusion cells, 3D skin constructs), and population-specific susceptibility factors (e.g., children, individuals with compromised skin). We elucidate how soil properties (pH, organic matter) and metal speciation (e.g., Cr(III)/Cr(VI)) modulate cutaneous uptake, and detail toxicological mechanisms including oxidative stress, ferroptosis/cuproptosis, immunotoxicity, and pigmentation disorders. Case studies reveal heterogeneous HM hotspots in high-traffic and densely populated areas, while in vitro–in vivo extrapolation highlights the potential for misestimation in traditional models. Consequently, we discuss the limitations and future directions of this framework, aiming to shift UGS risk management from over-conservative assessment to bioavailability-based precision governance, thereby supporting the health security of sustainable urban habitats.

## Linked entities

- **Chemicals:** Cr(III) (PubChem CID 27668), Cr(VI) (PubChem CID 29131)

## Full-text entities

- **Genes:** IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, GLB1 (galactosidase beta 1) [NCBI Gene 2720] {aka EBP, ELNR1, MPS4B}, Cxcl15 (C-X-C motif chemokine ligand 15) [NCBI Gene 20309] {aka Il8, Scyb15, lungkine, weche}, EDN1 (endothelin 1) [NCBI Gene 1906] {aka ARCND3, ET1, HDLCQ7, PPET1, QME}, MCU (mitochondrial calcium uniporter) [NCBI Gene 90550] {aka C10orf42, CCDC109A, HsMCU}, Il18 (interleukin 18) [NCBI Gene 16173] {aka Igif, Il-18}, Myd88 (myeloid differentiation primary response gene 88) [NCBI Gene 17874], SOD2 (superoxide dismutase 2) [NCBI Gene 6648] {aka GC1, GClnc1, IPO-B, IPOB, MNSOD, MVCD6}, MMP1 (matrix metallopeptidase 1) [NCBI Gene 4312] {aka CLG}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314] {aka CHDS6, MMP-3, SL-1, STMY, STMY1, STR1}, XBP1 (X-box binding protein 1) [NCBI Gene 7494] {aka TREB-5, TREB5, XBP-1, XBP2}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, ACSM3 (acyl-CoA synthetase medium chain family member 3) [NCBI Gene 6296] {aka SA, SAH}, ATP7B (ATPase copper transporting beta) [NCBI Gene 540] {aka PWD, WC1, WD, WND}, SLC31A1 (solute carrier family 31 member 1) [NCBI Gene 1317] {aka COPT1, CTR1, NSCT}, MMP10 (matrix metallopeptidase 10) [NCBI Gene 4319] {aka SL-2, STMY2}, SLC11A2 (solute carrier family 11 member 2) [NCBI Gene 4891] {aka AHMIO1, DCT1, DMT1, NRAMP2}, STAT6 (signal transducer and activator of transcription 6) [NCBI Gene 6778] {aka D12S1644, HIES6, IL-4-STAT, STAT6B, STAT6C}, ELN (elastin) [NCBI Gene 2006] {aka ADCL1, SVAS, WBS, WS}, HSPA5 (heat shock protein family A (Hsp70) member 5) [NCBI Gene 3309] {aka BIP, GRP78, HEL-S-89n}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, Il1 (interleukin 1 complex) [NCBI Gene 111343] {aka Il-1}, Nil (neonatal intestinal lipidosis) [NCBI Gene 110093] {aka Ml}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, DLAT (dihydrolipoamide S-acetyltransferase) [NCBI Gene 1737] {aka DLTA, E2, PBC, PDC-E2, PDCE2}, MITF (melanocyte inducing transcription factor) [NCBI Gene 4286] {aka CMM8, COMMAD, MI, MITF-A, WS2, WS2A}, FDX1 (ferredoxin 1) [NCBI Gene 2230] {aka ADX, FDX, LOH11CR1D}, CYP1A1 (cytochrome P450 family 1 subfamily A member 1) [NCBI Gene 1543] {aka AHH, CP11, CYP1, CYPIA1, P1-450, P450-C}, ATF6 (activating transcription factor 6) [NCBI Gene 22926] {aka ACHM7, ATF6A, ATP6alpha}, CYP1B1 (cytochrome P450 family 1 subfamily B member 1) [NCBI Gene 1545] {aka ASGD6, CP1B, CYPIB1, GLC3A, P4501B1}, MST1 (macrophage stimulating 1) [NCBI Gene 4485] {aka D3F15S2, DNF15S2, HGFL, MSP, NF15S2}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, H2AX (H2A.X variant histone) [NCBI Gene 3014] {aka H2A.X, H2A/X, H2AFX}, GPNMB (glycoprotein nmb) [NCBI Gene 10457] {aka HGFIN, NMB, PLCA3}, GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}
- **Diseases:** water (MESH:D000069578), melanoma (MESH:D008545), lead poisoning (MESH:D007855), epigenetic disorders (MESH:D009358), type IV hypersensitivity (MESH:D006968), tumor (MESH:D009369), AD (MESH:D003876), eczema (MESH:D004485), Pigmentation Disorders (MESH:D010859), neurological disorders (MESH:D009461), poisoning (MESH:D011041), immune dysregulation (OMIM:614878), hypersensitivity (MESH:D004342), dermatoses (MESH:D012871), Cutaneous Toxicity (MESH:D013262), Inflammation (MESH:D007249), Iron deficiency (MESH:D000090463), Barrier Dysfunction (MESH:C536830), carcinogenic (MESH:D011230), injury to (MESH:D014947), dermatitis (MESH:D003872), hyperpigmentation (MESH:D017495), cutaneous pigmentary disorders (MESH:C535508), carcinogenesis (MESH:D063646), contact dermatitis (MESH:D003877), cutaneous diseases (MESH:D004194), Neurotoxic (MESH:D020258), Toxicity (MESH:D064420), cardiovascular disease (MESH:D002318), HM (MESH:D000075322), ACD (MESH:D017449), mitochondrial damage (MESH:D028361), psoriasis (MESH:D011565)
- **Chemicals:** NAD+ (MESH:D009243), ROS (MESH:D017382), hydroxyl radicals (MESH:D017665), palladium (MESH:D010165), 2-ethylhexyldiphenyl phosphate (MESH:C018535), Vitamin E (MESH:D014810), Pb (MESH:D007854), SFN (MESH:C016766), Metals (MESH:D008670), Vitamin C (MESH:D001205), S (MESH:D013455), melanin (MESH:D008543), Copper (MESH:D003300), Ni (MESH:D009532), Cr(III) (-), Cadmium (MESH:D002104), Calcium (MESH:D002118), Mn (MESH:D008345), Chromium (MESH:D002857), HM (MESH:D019216), TCA (MESH:D014233), Hg (MESH:D008628), carbon (MESH:D002244), MDA (MESH:D008315), Arsenic (MESH:D001151), Fe (MESH:D007501), Cr(VI) (MESH:C074702), Co (MESH:D003035), lipid (MESH:D008055), hyaluronic acid (MESH:D006820), Zn (MESH:D015032)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Solanum lycopersicum (tomato, species) [taxon 4081], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** fibroblasts — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594), HaCaT — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0038)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13030796/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13030796/full.md

## References

130 references — full list in the complete paper: https://tomesphere.com/paper/PMC13030796/full.md

---
Source: https://tomesphere.com/paper/PMC13030796